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Background: To achieve globally or regionally defined accelerated disease control, elimination and eradication
(ADC/E/E) goals against vaccine-preventable diseases requires complementing national routine immunization
programs with intensive, time-limited, and targeted Supplementary Immunization Activities (SIAs). Many global and
country-level SIA costing efforts have historically relied on what are now outdated benchmark figures. Mobilizing
adequate resources for successful implementation of SIAs requires updated estimates of non-vaccine costs per
target population.
Methods: This assessment updates the evidence base on the SIA operational costs through a review of literature
between 1992 and 2012, and an analysis of actual expenditures from 142 SIAs conducted between 2004 and 2011
and documented in country immunization plans. These are complemented with an analysis of budgets from 31
SIAs conducted between 2006 and 2011 in order to assess the proportion of total SIA costs per person associated
with various cost components. All results are presented in 2010 US dollars.
Results: Existing evidence indicate that average SIA operational costs were usually less than US$0.50 per person in
2010 dollars. However, the evidence is sparse, non-standardized, and largely out of date. Average operational costs
per person generated from our analysis of country immunization plans are consistently higher than published
estimates, approaching US$1.00 for injectable vaccines. The results illustrate that the benchmarks often used to
project needs underestimate the true costs of SIAs and the analysis suggests that SIA operational costs have been
increasing over time in real terms. Our assessment also illustrates that operational costs vary across several
dimensions. Variations in the actual costs of SIAs likely to reflect the extents to which economies of scale associated
with campaign-based delivery can be attained, the underlying strength of the immunization program, sensitivities
to the relative ease of vaccine administration (i.e. orally, or by injection), and differences in disease-specific
programmatic approaches. The assessment of SIA budgets by cost component illustrates that four cost drivers make
up the largest proportion of costs across all vaccines: human resources, program management, social mobilization,
and vehicles and transportation. These findings suggest that SIAs leverage existing health system infrastructure,
reinforcing the fact that strong routine immunization programs are an important pre-requisite for achieving
ADC/E/E goals.
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Conclusions: The results presented here will be useful for national and global-level actors involved in planning,
budgeting, resource mobilization, and financing of SIAs in order to create more realistic assessments of resource
requirements for both existing ADC/E/E efforts as well as for new vaccines that may deploy a catch-up
campaign-based delivery component. However, limitations of our analysis suggest a need to conduct further
research into operational costs of SIAs. Understanding the changing face of delivery costs and cost structures for
SIAs will continue to be critical to avoid funding gaps and in order to improve vaccination coverage, reduce health
inequities, and achieve the ADC/E/E goals many of which have been endorsed by the World Health Assembly and
are included in the Decade of Vaccines Global Vaccine Action Plan.Background
Over the past three decades, several global health initia-
tives have brought together public and private stake-
holders to focus efforts on achieving globally or regionally
defined goals of accelerated disease controla, elimination
and eradication (ADC/E/E) of several vaccine-preventable
diseases—notably poliomyelitis (polio), measles/rubella,
maternal and neonatal tetanus (MNT), yellow fever, and
Neisseria meningitis serogroup A (menA) [1-8]. These
initiatives have combined strategic focus, global coordin-
ation, expertise, and capacity to assist country govern-
ments mainly in low income countries (LICs) and middle
income countries (MICs), complementing national rou-
tine immunization activities with intensive, time-limited,
and targeted vaccination campaigns – Supplementary
Immunization Activities (SIAs) [9-11]. At best, well-
funded SIAs represent an important delivery strategy to
improve population immunity, reduce inequities in ac-
cess to vaccination, and help achieve ambitious public
health goals.
Prices of the vaccines used in ADC/E/E initiatives have
reached maturity in that they are relatively affordable (i.e.
roughly $0.50 per dose or less) and in most cases supply
and prices are quite stable [12]. From a funding stand-
point, the cost of these vaccines have historically been
covered by global financers of immunization such as the
GAVI Alliance (formerly the ‘Global Alliance for Vaccines
and Immunizations’); or vaccine costs have been covered
by the resources mobilized by the partnerships that have
coalesced around ADC/E/E efforts like the Global Polio
Eradication Initiative (GPEI) and the Measles-Rubella Ini-
tiative (MRI). However, since the late 1990s, the increasing
number of ADC/E/E as well as other health priorities has
increased competition for resources. Funding from both
national and global sources has often been insufficient to
cover vaccine and non-vaccine SIA costs, but particularly
the operational costs of SIAs. Along with a variety of other
factors, funding shortfalls have led to delays in implemen-
tation or forced SIA efforts to be scaled back (i.e. to target
narrower age groups) resulting in campaigns not reaching
the necessary coverage rates nor the levels of population
immunity necessary for disease control, in some casesresulting in large disease outbreaks after re-introduction
of virus [13-16].
SIA funding shortfalls are likely to have been precipitated
by a number of factors: ADC/E/E programs essentially de-
liver a ‘global good’ whose benefit may be underestimated
on a national basis leading to underinvestment by national
payers. The somewhat unpredictable nature of disease dy-
namics associated with many of the viruses targeted by
ADC/E/E efforts may make longer term planning and bud-
geting for SIAs difficult at the national level. The broad age
ranges targeted particularly with catch-up SIAs, and to a
lesser extent follow-up SIAs, is likely to stretch national
health budgets particularly where external partner funding
(e.g. from GAVI Alliance or MRI) is not available. While
weak governance within many of the countries that are
worst affected by these diseases almost certainly limits the
effectiveness of monies earmarked for SIAs.
Combining the above factors with the lack of informa-
tion about the real operational costs of SIAs, how these
costs differ by disease, delivery strategy, and setting, and
how they may be changing over time, may have hampered
the ability of payers at both country- and global levels to
allocate adequate funds to cover SIA costs.
Looking ahead and beyond the existing ADC/E/E ini-
tiatives, it is clear that over the coming decade SIAs will
continue to be an integral part of vaccination delivery strat-
egies in combination with routine vaccine delivery (through
outreach and fixed site –based approaches). Several under-
utilized and new vaccines that seem likely to be adopted
across LICs and MICs in the coming years will include an
SIA delivery component: either a one-time catch up cam-
paign at the time of introduction to accelerate disease
control (i.e. Japanese Encephalitis (JE) vaccines, typhoid
conjugate vaccines), or periodic campaigns to maintain
herd immunity (i.e. cholera vaccines) [17]. For these newer
or still underutilized vaccines, all of which are components
of the global immunization agenda set out in the Decade of
Vaccines (DoV) Global Vaccine Action Plan (GVAP), there
is limited evidence on the costs of campaign-based delivery
making it more difficult to predict the necessary resource
requirements to achieve the DoV goals [18-22]. Until such
tailored evidence can be generated, the most up-to-date
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be critical for long range financial planning.
Objectives
The objectives of the work described in this paper are to:
 review published and grey literature on the
operational costs associated with implementation of
SIAs and summarize the results;
 estimate the average operational costs associated
with implementation of SIAs based on actual costs
reported by countries;
 compare older estimates of operational costs (from
2004–2008) from literature to more recent estimates
(from 2009–2011);
 explore how average operational costs vary by
vaccine, geography, and program;
 assess the main cost components of operational
costs from available budget data; and to
 discuss the policy and practice implications of these
findings for future SIA efforts.
Methods
The research was divided into two parts – (I) A litera-
ture review; and (II) An analysis of data from country-
specific and global immunization plans and budgets.
(I)→Literature review
A review of the relevant literature, both the peer-reviewed
and non-peer reviewed grey literature, between 1992 and
2012 was conducted using the PubMed database with the
aim of identifying SIA operational costs estimates and
expenditures. The review used the following inclusion
criteria:
 Paper must deal with an SIA to deliver human
vaccines rather than veterinary vaccines;
 Paper must deal with an SIA conducted in an LIC
or MIC;
 Paper’s emphasis must be on SIAs/mass vaccination
campaigns rather than communications/media
campaigns that might be related to vaccination efforts;
 Paper must include primary source data on the
operational costs of SIAs;
 Paper must include operational cost data that can be
separated from the costs of vaccines, and expressed
on a per person targeted/vaccinated basisb;
 Paper must have an available English language
abstract.
Search terms included: “supplement* immunization ac-
tivity cost”, “SIA cost”, “vaccin* campaign cost”, “mass
vaccin* cost”, “vaccin* operational cost”, “polio eradication
cost”, “measles elimination cost”, “vaccin* disease controlcost”. Spelling variations and permutations of these search
terms were also included.
To ensure comparability, we specified all operational
costs on a per targeted person per dose basis to control
for differences in vaccination course. Where possible we
attempted to control for differences in costing defini-
tions, in particular excluded opportunity costs, indirect
costs, the costs of vaccines, injection supplies, freight and
customs charges (for international shipment of vaccines),
and international technical assistance to support the SIAs
including agency overhead costs. We also controlled for
temporal distortions by inflation adjusting cost estimates
into 2010 dollars using published deflators and converting
costs from local currencies into United States dollars (US$)
using published historic exchange rates [23,24]. Finally, we
drew upon and extended a previously published framework
as a template for summarizing papers containing SIA oper-
ational costs [25].
(I)→Analysis of data from country-specific plans – See
Additional file 1
Analysis description
A previous unpublished analysis of costed country
immunization plans assessed the operational costs per
person for many of the vaccines noted above (P. Lydon
and G. Gandhi: Introduction of New Vaccines: Analysis
of non-vaccine routine and campaign costs for the GAVI
Alliance. Unpublished). The previous analysis was based
on a heterogeneous dataset that included actual costs
and expenditures as well as projected costs. Since pro-
jections often rely on out of date benchmarks or historic
expenditures, the unpublished study may have underesti-
mated the true operational costs of SIAs. In this paper, we
update the analysis restricting to a more homogenous and
valid dataset (discussed in more detail below in the Ana-
lytic approach), and extend the analysis to illustrate how
per person operational costs varied in aggregate by:
(i) Temporal characteristics – to assess how costs have
changed over time.
 Comparing estimates identified in the literature
with those generated from comprehensive multi-
year plans (cMYPs) data.
 Comparing older estimates (from 2004–2008)
from cMYPs versus more recent estimates (from
2009–2011) in aggregate across the dataset, as
well as on a country-by-country basis where a
country has conducted two SIAs against the same
vaccine-preventable in the two time periods.
(ii)Vaccine delivery characteristics – to assess the
effects on costs of different target populations and
methods of administration.
 Comparing Oral Polio vaccines (OPV) and
measles vaccines both targeting mainly under-five
Figure 1 Distribution of SIA expenditure estimates by
vaccine-preventable disease, 2004–2011 – cMYP data (N=142).
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measles vaccines), and tetanus-containing vaccines
(e.g. tetanus toxoid—TT, tetanus-diphtheria—Td
vaccines) targeting at-risk women of child bearing
age (WCBA) populationsc.
 Comparing interventions administered orallyd
versus injectable vaccination.
(iii) Country characteristics – to assess the effects of
population size, region, and program strength.
 Comparing two country groupings by population
size: Midsize/Large Countries with total
population ≥ 10 million, and Small Countries
with total population <10 million)e.
 Comparing geographic regions as defined by the
World Health Organization (WHO) regional
groupings [26].
 Comparing the underlying strength of the routine
immunization program, using estimated levels of
vaccination coverage at the time the SIA was
conducted, as a proxy (Grouping countries with
coverage ≤ 70%, countries with coverage between
71% and 89%, and countries with coverage≥ 90%)f.
We also analyzed the operational costs across the port-
folio of vaccines that have a campaign-based delivery
component (i.e. JE, measles, measles-rubella (MR), menA,
typhoid, and yellow fever vaccines) and that the GAVI Al-
liance supports or has committed to support [27]. In par-
ticular, we sought to assess how the actual operational
cost expenditures compare to the levels of support that
GAVI offers to countries conducting SIAs; namely
US$0.30 per targeted person for SIAs conducted between
2004 and 2012, and US$0.65 per targeted person there-
after [28].
Data sources
The primary source for this analysis was country-specific
data from cMYPs submitted to the WHO and the
United Nations Children’s Fund (UNICEF) in 2009 and
2011 [29]. cMYPs are used mainly by immunization
program managers in LICs and MICs to articulate a
long-term costed plan for a national immunization pro-
gram. For the reference-style data underlying the ana-
lysis (e.g., country population size data, GDP deflators),
we employed datasets validated by third-party multilat-
eral agencies [30,31].
Analytic approach
Each cMYP records actual cost data for a ‘baseline year’,
followed by a five-year projection period in which future
costs of the program are estimated. We extracted and
aggregated operational cost data and total target popula-
tion data per SIA conducted from the cMYP baseline
years alone in order to focus on the best quality andmost homogeneous actual informationg. The cost data
were consolidated and inflation-adjusted into 2010
dollars [23]. The inflation-adjusted operational costs per
SIA were then combined with data on relevant target
populations specified in the cMYP in order to control
for the different target populations of campaigns and to
generate standardized operational costs metrics on a
population-weighted per person basis.
Sample descriptive statistics
The extracted baseline cMYP data constitutes 142 SIA
country observations of SIA operational costs from 70
cMYPs produced by 40 countries; i.e. several countries
developed more than one cMYP, and several countries
conducted more than one SIA over the analytical period.
Of the 142 observations, 75 are from the period 2004–
2007 while 67 are from the period 2008–2011. The dis-
tribution of the data by vaccine is illustrated in Figure 1.
In terms of country size and geographic location, 64%
of the SIA observations were for Midsize/Large countries,
versus 36% for Small countries. Of the observations, 66%
were for SIAs conducted in the African region (AFR), 21%
in the Eastern Mediterranean (EMR), 11% in South East
Asia (SEAR), and the remaining 2% in Western Pacific
(WPR) and European (EUR) regions [26]. There were no
SIA observations for the Americas region (AMR) because
cMYPs are not produced in the same format for countries
in this region. Given this regional distribution, only the
average operational costs for AFR, EMR and SEAR are
presented here since WPR/EUR observations were insuffi-
cient to draw out any meaningful results. In terms of
immunization program capacity/performance as measured
by vaccination coverage, 23% of all the country observa-
tions were from countries with DTP3 ≤ 70% at the time
the SIA was conducted, 45% from countries with DTP3 be-
tween 71% and 89%, and 32% from countries with DTP3 ≥
90%. By contrast, using MCV1 coverage, the distribution
Gandhi and Lydon BMC Public Health 2014, 14:67 Page 5 of 16
http://www.biomedcentral.com/1471-2458/14/67of countries is markedly different; 49% of countries had
MCV1 ≤ 70% at the time the SIA was conducted, 32%
from countries with MCV1 between 71% and 89%, and
19% from countries with MCV1 ≥ 90%. Finally, in terms of
country wealth as measured by per capita income, the vast
majority of countries (71%) were classified as Low Income
Countries (LICs) by the World Bank at the time of con-
ducting the SIAs, while the remainder of the sample was
classified as Lower Middle Income Countries (LMICs).
(I)→Analysis of data from country-specific budgets – See
Additional file 1
Analysis description
Separate from the interrogation of expenditures described
above, an analysis of SIA budgets was undertaken to
understand the main cost components of campaign oper-
ational costs. Budget data on operational costs was
assessed in aggregate by Vaccine delivery characteristics.
The sample size was too small to enable meaningful as-
sessment of the data by temporal or country characteris-
tics (although the planned timing of the campaigns and
country characteristics are noted in Additional file 1).
Data sources
Budget data were used for the analysis of operational
cost components because cMYP data do not disaggre-
gate operational cost and expenditure information by
cost component. SIA budgets came from a variety of
sources: Budget breakdowns are requested as part of
previous GAVI New Vaccine Support (NVS) application
forms so these were used largely to provide a picture of
menA and yellow Fever SIA operational cost compo-
nents [32]. In addition, SIA budget information is often
shared with ADC/E/E program coordinators at WHO,
UNICEF and other technical agencies involved in these
initiatives and particularly for measles and tetanus SIAs.
For the reference-style data, we again employed datasets
validated by third-party multilateral agencies [30,31].
Analytic approach
For the analysis of operational cost components, the
various campaign budgets from 31 SIAs conducted be-
tween 2006 and 2011 were coded into a standardized
format, and inflation-adjusted into 2010 dollars. These
data were then analyzed to assess the proportion of total
SIA costs per person for each cost component.
Sample descriptive statistics
The campaign budget analysis relied on a much smaller
sample – 31 SIAs, of which 32% were for measles vac-
cines, 29% Tetanus, 26% menA, and 13% yellow fever.
The majority (68%) of these SIAs were planned to take
place in countries in the AFR region, most (77%) in
mid-sized or large countries (i.e. countries with totalpopulations >10 million), and most (58%) in countries
with MCV1 between 71% and 89%. Equally, most (58%)
of the budgets were for LICs.
Results and discussion
(I)→Literature review
Searches yielded 394 unique results. Of these, 381 were
excluded following review of their abstracts because they
were found not to meet the inclusion criteria – The
remaining 13 manuscripts were then reviewed and per-
tinent information was extracted. Four further citations
of papers/unpublished reports not identified in the initial
searches were retrieved and assessed against the inclu-
sion criteria. Overall, 17 papers and reports met the in-
clusion criteria.
Table 1 illustrates the summary findings from the
remaining papers. Outside of measles vaccine SIAs, data
is sparse, and surprisingly so for OPV and TT SIAs given
their frequency. The vast majority of estimates come
from studies conducted 10+ years ago, and mainly in the
African region. All operational costs per person per dose
were in the region of US$0.50 (median: $0.33; range:
$0.03-$0.79) and all under US$1.00.
Distinction between average and incremental costs is
often not made explicit in the literature reviewed. That
said, since SIAs tend to be additional to the provision of
routine health services, the majority of costs incurred can
be considered as incremental rendering these distinctions
less relevant. Most of the publications reviewed separated
costs into fixed and variable costs, specified the cost com-
ponents included (albeit using different terminologies and
categorizations), and defined the perspective taken [and
hence whether economic and/or financial (or accounting)
costs, indirect and/or direct costs had been included].
However, studies were less consistent about acknowledging
and distinguishing between immunization-specific versus
shared costs, and whether/how depreciation for capital
equipment was factored into their analyses. In some in-
stances (notably for OPV + measles + VitA SIAs) cam-
paigns were performed in an integrated fashion. In these
instances, authors assumed that aside from the costs of
vaccines and supplies, other cost components could not be
assigned to each antigen/intervention and assumed they
would have been the same regardless of whether one inter-
vention or multiple interventions were delivered through
the SIA. Variability in these definitions and costing prac-
tices makes comparing across the published literature
difficult. Furthermore, the information detailed in Table 1
should be read with the above caveats in mind.
(II)→Analysis of country-specific plans data – See
Additional file 2
Given the low number of observations for menA, yellow
fever, MR and ‘Other’ SIAs in the dataset, average per



































mnths - 12 yrs.
External donor Retrospective Incremental 2002 $0.194 N/A Training, incentives (per diems),
transport, monitoring, social





























Retrospective Average 2001 $0.284 $0.41 (2005) Micro- planning, social
mobilization, training, transport,












Retrospective Average 2000 $0.562 N/A Transport and travel, salaries and
per diems, supervision, training,
other campaign-specific costs
Nationwide























Retrospective Average 2000 $0.312 N/A Transport and travel, salaries and
per diems, supervision and
training, other campaign-specific
costs (includes social mobilization
surveillance)


























































































Retrospective Incremental 1994 $0.657 /A Personnel [including per diems
for all staff involved in SIA(iii)];
publicity and social promotion;
training costs, logistical costs
(including shipping, freight, fuel,

















National payer Not specified Incremental 2001 $0.491 N/A Training, social mobilization, per
diems, salaries (of health workers,
vaccinators, and supervisors),
rental of vehicles, fuel, ice for cold


























National payer Retrospective Average 2001 $0.224 N/A Transport (inc. fuel and




















National payer Prospective Incremental 1997 $0.074 N/A Staff costs (per diems and travel
costs), transport (inc. fuel,
maintenance and repairs), cold
chain equipment, social/
community mobilization,

































































Prospective Average 2006 $0.507 N/A Transportation, personnel, IEC/
social mobilization, supervision,
surveillance, monitoring &










































National payer Retrospective Average 1997 $0.787 N/A Transport, vaccination cards,
storage (free of charge), material
for administration, material for

















National payer Retrospective Average 1998 $0.142 N/A Personnel, training, review
meeting, and social mobilization
(Publicity/information campaign)
(i)But excludes UNICEF staff costs, UNICEF and the Federal Ministry of Health’s overhead costs.
(ii)Excludes recurrent costs involved in the running of international organizations.
(iii)i.e. managers, supervisors, cold-chain technicians, drivers, vaccinators.
(iv)Subjects with acute progressive diseases and immune deficiency were excluded.
(v)Polysaccharide A + C meningococcal vaccine.
(vi)Household costs presented elsewhere.
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http://www.biomedcentral.com/1471-2458/14/67person operational costs for these vaccines were not an-
alyzed separately. The observations for these vaccines
are included in other aggregate operational cost indica-
tors presented – for the following groups of vaccines:
 Vaccines in GAVI’s portfolio – Based on 51 SIA
expenditure observations for measles (n=38), MR
(n=3), menA (n=6), yellow fever (n=1), JE (n=2), and
typhoid (n=1) vaccines.
 Injectable vaccines – Based on the 51 observations
listed above for ‘Vaccines included in the GAVI
portfolio’ plus a further 28 observations for tetanus
(26), hepatitis B (n=1) and pertussis (n=1) vaccines.
 Orally administered vaccines/interventions – Based
on 63 observations for OPV (n=53), vitamin A (n=8)
and albendazole/mebendazole (n=2) tablets.
Table 2 summarizes our estimates of (population
weighted) average operational costs per person from the
cMYP data.
Analysis of cMYP data
Focusing on the results for ‘All countries’ (in Table 2)
and outside of OPV/oral interventions and tetanus vac-
cines, average operational costs per person per dose for
this analysis are around US$0.75 to US$1.00. Comparing
results in Table 2 versus Table 1 in general, as well as onTable 2 Weighted Average per person per dose operational c






OPV $0.40 53 $0.54 22 $0
Tetanus vaccines $0.29 26 $0.80 7 $0
Measles vaccines $0.81 38 $1.30 13 $0
Vaccines in GAVI’s portfolio $0.98 51 $1.07 17 $0
Oral vaccines/
interventions
$0.39 63 $0.46 27 $0
Injectable vaccines $0.77 79 $0.98 24 $0




‡→Minimum values: In terms of the frequency of occurrence of extremely low valu
observations below $0.10. Seven of these instances related to SIAs for orally admin
were for tetanus vaccine SIAs which, on average, have lower operational costs in an
not significantly change the findings. While it’s possible that the extremely low valu
analyses because they seemed plausible. From an analytic perspective, where low v
diseases, and over time. In the majority of cases where the operational costs were l
From a programmatic and budgetary/planning perspective, there are a variety of p
the campaign without needing to acknowledge these in the budget; re-programmi
vaccinate children during the SIA) without this shared cost featuring in the immuni
community health workers to undertake campaign vaccination). It is not uncommo
volunteer time [47].
§→Maximum values: Similarly, while it’s possible that the extremely high values cou
again because they appeared plausible. 9% of the dataset (n= 13 occurrences) whe
were in very small countries (e.g. Cape Verde, Djibouti, Kiribati); two involved vaccin
target groups (i.e. typhoid vaccines for food handlers in schools, Hepatitis B targetin
where per diems often raise the average SIA costs (See below for further details).a country-specific basis (in the penultimate column of
Table 1), operational costs from the new analysis of
country plans are generally higher than published esti-
mates. Since all cost estimates presented have been ad-
justed for inflation, the results suggest that costs have
increased over time in real terms.
Looking at how operational costs have changed over
time within the sample of cMYPs themselves, and spe-
cifically comparing in aggregate more recent operational
SIA costs from campaigns conducted over the period
2009–2011 to older estimates from campaigns conducted
over the period 2004–2008, we find that across vaccines,
more recent campaigns are consistently higher, particularly
for OPV SIAs (Figure 2). While pairwise comparisons of
operational cost estimates in cMYPs on a country-by-
country basis, we find that in almost all cases, average per
person operational costs have increased markedly, and
again particularly for OPV SIAs (Figure 3). One explan-
ation for these increasing trends in costs might be that
as the eradication program draws closer to achieving its
goal, program officials have increasingly focused re-
sources and efforts on immunizing the hardest (and
most costly) to reach and most underserved communi-
ties. Of course, since these communities are often at
greatest risk of vaccine-preventable disease, these re-
sults do not diminish the case for achieving more equit-
able vaccination coverage.osts by vaccine/grouping and size of the country,
n ‡ Max§ SD Mid-size & large
countries (≥10 m)
N Min ‡ Max§ SD
.14 $1.97 $0.42 $0.39 31 $0.02 $1.77 $0.29
.02 $1.83 $0.32 $0.27 19 $0.02 $0.76 $0.13
.27 $3.73 $0.68 $0.79 25 $0.13 $3.55 $0.57
.05 $9.52 $1.44 $0.98 34 $0.03 $3.55 $0.69
.10 $1.97 $0.42 $0.39 36 $0.004 $1.77 $0.33
.02 $9.52 $1.45 $0.76 55 $0.02 $3.55 $0.73
91
es, of the 142 country observations in the dataset, 8% (n=12) of the country
istered vaccines/intervention for which we would expect lower costs, and three
y case. A sensitivity analysis indicated that removing these observations did
es could signify errors in the country plans, these were included in the
alues were observed, we compared these within a countries’ cMYP across
ow, the estimates were consistently low suggesting that these were not errors.
ossible explanations; e.g. reliance on partners or CSOs to conduct (aspects of)
ng existing health sector staff to conduct campaign (e.g. making nurses
zation budget; reliance on unpaid personnel to conduct campaign (e.g.
n for immunization costing studies to overlook donated costs including that of
ld signify errors in the country plans, these were included in the analyses
re average operational costs were greater than $1.50 per person. Of these, five
es not usually administered through mass vaccination and/or very specific
g special risk groups), and all bar-one were conducted in the African region
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per dose operational costs are lower for Midsize/Large
Countries than Small Countries, most likely because
there are significant economies of scale associated with
the conduct of SIAs. Operational costs had a tendency
to be lower for OPV and orally administered interven-
tions compared to injectable vaccines, likely explained
by the fact that such vaccines/interventions are easier to
administer. Personnel delivering these interventions are
often ‘lay vaccinators’ (i.e. they may not be skilled health
workers qualified to administer injections) and therefore
may receive lower salaries, require less training and less
costly supervision, all of which can reduce the operational
costs.
Operational costs for measles vaccine SIAs are, on
average, higher than for OPV and tetanus vaccine SIAs;
and since measles vaccine observations dominate the
sample used to define operational costs of vaccines in
GAVI’s portfolio, these costs are also higher. By contrast,
average per person operational costs of tetanus vaccine
SIAs appear to be lower than other injectable vaccines.
Since cMYP data do not offer breakdowns of cost drivers
it is not possible to explain definitively from a program-
matic standpoint what might be driving these differences.
While further research would be needed to provide a de-
finitive answer, we hypothesize that the lower operational
costs associated with tetanus vaccine SIAs may in part re-
late to the district-specific targeting strategy used in MNT
elimination SIAs known as the “high risk approach”–
WCBA living in specific high risk districts (HRDs) are
targeted with three properly spaced doses of TT [48].
Since these SIAs are almost always conducted sub-
nationally in a subset of districts, there is greater ability to
work with local antenatal staff and/or local community
health workers (CHWs) based in those districts rather
than bringing in external vaccinators. Since these localFigure 2 Percentage change in operational costs across the dataset c
between 2004 and 2008) with more recent estimates (for SIAs conduworkers generally reside in the community they serve,
their proximity to their target population reduces the need
for a daily subsistence allowances (“per diems”) over and
above basic salaries that would otherwise be factored into
operational costs for SIAs conducted nationally. Such
localized efforts generally require less extensive supervi-
sion, and more modest social mobilization, communica-
tion and advocacy (e.g. to publicize efforts on television
and radio) efforts.
Average operational costs are consistently higher in
the African region (Figure 4) and it is possible that this
at least partly relates to a practice most prevalent in
AFR, of offering per diems to health workers, particu-
larly for training and outreach activities [49]. However,
reaching target populations is generally considered more
challenging in AFR as a result of weak infrastructure, and
could be a significant factor driving higher operational
costs in this region.
Figure 5 illustrates the average operational costs per
person by vaccine grouping and strength of the under-
lying routine immunization program. Despite the differ-
ent distributions when using DTP3 or MCV1 coverage
as the proxy indicator of system strength (described in
the sample characteristics above), both indicators suggest
a negative inverse relationship between program strength
and operational costs.
(III)→Analysis of country-specific budgets – See
Additional file 2
The breakdown of SIA operational costs by cost compo-
nent illustrates that four cost drivers make up the largest
proportion of costs across all vaccines: human resources
(i.e. salaries, per diems), program management, social
mobilization (e.g. information, education, communica-
tion and advocacy), and vehicles and transportation (e.g.
fuel to transport vaccinators). The fact that cold chainomparing older expenditure estimates (for SIAs conducted
cted between 2009 and 2011) – Analysis of cMYP data.
Figure 3 Percentage change in country-specific operational costs (per targeted person per dose) over given time periods – Analysis of
cMYP data.
Gandhi and Lydon BMC Public Health 2014, 14:67 Page 11 of 16
http://www.biomedcentral.com/1471-2458/14/67equipment makes up such a small proportion of oper-
ational costs suggests that SIAs build on existing routine
immunization systems and do not require significant
additional capital investment (Figure 6).
Compared to other vaccine SIAs, as a proportion of
total operational costs Tetanus vaccine SIAs tend to be
associated with higher human resources and training
costs, and lower vehicles and transportation costs, and
virtually no cold chain cost. This finding supports the
notion that the HRD approach used in MNT elimination
SIAs rely on training local health staff rather thanbringing in external vaccinators. While Yellow Fever
budget breakdowns also differ from other vaccine SIAs,
this variance may be more associated with outliers in the
small number of observations in the budget sample.
(IV)→Limitations
Our analysis of operational costs of SIAs represents a
minority of the total SIAs conducted worldwide over the
analytical period. For example, our analysis of country-
specific plans covered around 11% (41/360) of the mea-
sles/rubella-containing vaccine follow-up and catch-up
Figure 4 Average operational costs per targeted person per dose (US$) by vaccine grouping and WHO region, 2004–2011 – Analysis
of cMYP data.
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and 2011 [50]. Since mainly GAVI (eligible and graduat-
ing) countries report their immunization expenditures in
cMYPs, it is likely that our estimates represent a mean-
ingful summary for this segment of countries, rather
than more broadly. Similarly, because cMYPs are not
produced by AMR countries, the analysis of country
plans is not necessarily reflective of the situation in the
Americas. Finally, looking the literature and budget data
available, these are heavily skewed towards the AFR re-
gion (where the majority of SIAs have historically been
conducted) which also limits the applicability of these
findings to other regions.
The information documented in both existing litera-
ture and possibly the data from cMYPs may not be
reflective of the full costs of implementing an SIA. In
addition to the operational costs incurred mainly by na-
tional payers and reported in the literature and cMYPs,
implementation of SIAs that are part of global ADC/E/E
efforts often rely on additional expertise from global
agents such as WHO, UNICEF, and the United StatesFigure 5 Operational costs per person by vaccine and strength of the
for program strength), 2004–2011 – Analysis of cMYP data.Center for Disease Control and Prevention (US CDC).
These agencies provide highly specialized assistance to
governments—undertaking disease surveillance and la-
boratory testing to monitor epidemiologic dynamics and
to help target SIA efforts; developing/implementing so-
cial mobilization programs to strengthen community
demand for vaccination; and providing other technical
support (for example, to bolster program management
and training of vaccinators) — ultimately to improve the
quality of the campaigns. The costs associated with these
additional support activities are often referred to as “core
costs” in agency budgets but are rarely factored into esti-
mates of operational cost estimates to illustrate the true
nature of SIAsh.
Finally, the results of the cost analyses presented here
are only as strong as the data on which they rest. There
are many benefits of cMYPs; e.g., from a global perspec-
tive these country plans provide data on immunization
program costs (including operational costs of campaigns)
across a wide array of countries in a standardized form
and using a comparable methodology. However, cMYProutine immunization program (using DTP3 or MCV1 as a proxy
Figure 6 Breakdown of SIA operational costs, 2006–2011 (Relative share in %) – Analysis of SIA budget data.
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able quality. It is difficult to know what is included in each
country’s cMYP estimate of SIA operational costs since
breakdowns by cost components are not provided. Thus,
despite the availability of guidelines and templates for de-
tailed SIA budgetary planning [51,52], it is possible that
variable definitions are used from country to country plan.
Looking at the budget data where breakdown are pro-
vided, the number of budgets available and analyzed was
small. As such, these findings too should be interpreted
with care.
Conclusions
Elimination and eradication of vaccine preventable disease
represent the ultimate in addressing health inequities on a
local and global scale respectively, while accelerated dis-
ease control represents the next best alternative. Achiev-
ing ADC/E/E goals is seen as a public health imperative
but success since smallpox eradication has been elusive.
Robust planning and budgeting, adequate financing, good
governance, and effective implementation of SIAs building
on strong routine immunization programs are critical to
achieving these goals. Our analyses illustrate that existing
evidence that often informs budgeting, planning and fi-
nancing decisions, is out of date, and for many programs,
operational costs may be higher than previously thought.
Underestimation of costs and funding shortfalls can lead
to SIA implementation delays, and can force implemen-
ters to target narrower age groups undermining efforts to
reach program goals. Therefore, the results of the analysis
presented here may provide national and global-level
actors with newer SIA operational cost benchmarks to in-
form planning, budgeting, and financing decisions in ab-
sence of better information.
Our analyses also illustrate where program implemen-
ters might focus efforts to seek out efficiencies tomanage the upward trends in SIA operational costs. For
example, with a significant proportion of costs related to
human resources, given that there is often criticism of the
culture of per diems related to development assistance
[53], new assessment of the most cost effective ways to im-
plement SIAs may focus on this and other major cost
drivers.
While the information presented here updates the evi-
dence base, there is a need for continued monitoring
and additional research into SIA operational costs and
expenditures. These efforts might address the deficien-
cies and discrepancies in monitoring and reporting of
operational costs that are highlighted in our review of
the literature. Future research might build on the work
presented here using more sophisticated multivariate
analysis techniques to explore the extent to which each
of the factors identified above (e.g. geographic region, popu-
lation size, breadth of the target population, route of ad-
ministration, and the strength of the routine immunization
program as measured by vaccination coverage) explain and
influence operational costs. Future research efforts might
also seek to tie operational costs observed to intermediate
outcomes such as coverage, or better still final outcomes
like confirmed levels of population immunity so as to
understand how different levels of investment in SIAs affect
outcomes.
There are a number of areas that have yet to be fully
explored where future research/monitoring efforts may
focus – most notably to tease out the impact on SIA op-
erational costs of routine system strengthening efforts
embedded within SIAs. ADC/E/E program strategies are
again pointing to the fact that the key to their success
lies not just in high-quality and well-funded SIAs, but in
effective routine immunization programs built of strong
health systems [54]. Creating more robust routine sys-
tems requires its own investment increases (P. Lydon, G.
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cost of delivering routine vaccination in low & middle-
income countries: What is needed over the next decade?,
Submitted), but where successful, these efforts should
provide a broader platform for ADC/E/E programs to
reach all communities – ultimately reducing the mar-
ginal costs of vaccinating each additional child as illus-
trated by our findings. By contrast however, there are
also calls to exploit the visibility and resources of SIAs in
order to strengthen routine immunization (e.g. through
training routine health workers, procuring cold chain
equipment, and improving injection safety and adverse
events management), and there is evidence that such
approaches are feasible and can have a positive impact
[55-57]. While strengthening routine programs through
SIAs could reduce the frequency with which these SIAs
are needed, there is anecdotal evidence from measles SIAs
(comparing follow-up SIAs – where system strengthening
efforts are often embedded – to wide age range catch-up
SIAs where no system strengthening is undertaken) that
strengthening routine programs through SIAs will in-
crease the per person costs of those campaigns (Robert
Perry: Personal communication; 2013).
New research might also focus on the effect of grow-
ing security needs on operational costs. Recent attacks
on vaccinators, particularly those conducting OPV SIAs
in remote areas of the remaining polio endemic coun-
tries, are hampering ADC/E/E efforts [58,59]. Additional
costs of security for vaccinators in the likes of Northern
Nigeria, Pakistan and Afghanistan may drive up SIA costs
particularly for SIAs conducted in these areas. Document-
ing and factoring in these additional costs will be import-
ant to ensure SIA budgets are sufficient to overcome these
challenges.
Finally, the focus of new studies may need to go be-
yond existing ADC/E/E programs discussed here. As
aforementioned, several underutilized and new vaccines
that seem likely to be introduced in the coming years
have an SIA delivery component as one-time catch-up
strategies, or to periodically maintain herd immunity.
Better understanding of the costs of SIAs and how these
are likely to change over time will enable more robust
assessment of future ADC/E/E policies [60] and help in-
form the design of new financing strategies to facilitate
the large but infrequent investments associated with
catch up and follow up SIAs.
Endnote
aEncompassing epidemic prevention.
bOperational costs are normally expressed on a “per per-
son” basis. In some instances, these data are expressed on
a “per dose” basis. Where there was insufficient informa-
tion in the paper to express the information on a per per-
son basis, we excluded the paper.cThese were the vaccines and programs for which we
had sufficient data to draw out vaccine delivery -specific
findings; i.e. for menA SIAs targeting the populations
below 29 years of age, or yellow fever SIAs targeting
those below 60 years of age, there were insufficient ob-
servations to assess how operational costs for these vac-
cines/age groups compared to OPV, measles and TT/Td
vaccines.
dSince Albendazole/Mebendazole for de-worming and
Vitamin A (VitA) are often delivered in campaigns and
because many countries have estimated the operational
costs of delivering these interventions within their cMYPs,
these were included in the per person average costs of or-
ally administered interventions along with OPV.
eThese population grouping cut-offs were determined
based on the countries included in the analysis dataset,
balancing a need to ensure sufficient observations in
each grouping to explore meaningful differences in oper-
ational costs for small versus midsize/large country both
by vaccine, route of administration, and overall while
simultaneously grouping similar sized countries together
(at least where we expect there to be fewest economies
of scale—for small countries).
fThese cut-offs were selected based on published pol-
icy/strategy targets associated with the third dose of
Diphtheria-Tetanus-Pertussis (DTP3): The GAVI eligi-
bility policy permits countries to apply for most of the
routine new/underutilized vaccines so long as they have
DTP3 coverage equal to, or greater than 70% [61]. Sep-
arately, one of the goals of Global Immunization Vision
and Strategy (GIVS) defined in 2005 and reiterated in
the DoV GVAP is to reach 90% DTP3 coverage in all na-
tional immunization programs [62,63]. However, we also
used the same cut-offs when using the first dose of
measles-containing vaccine coverage (MCV1) as an alter-
native proxy for immunization program strength.
gAs aforementioned, and unpublished analysis of a lar-
ger dataset including actual expenditures and projected
operational cost data is presented elsewhere (P. Lydon
and G. Gandhi: Introduction of New Vaccines: Analysis
of non-vaccine routine and campaign costs for the GAVI
Alliance. Unpublished). The larger dataset covered 257
SIAs and was extracted from 87 unique cMYPs pro-
duced by 55 countries – Comparing the results gener-
ated from the larger but more heterogeneous dataset of
257 observations with the data/results presented in this
paper, the estimates for the former were mostly lower
than from the latter.
hAlthough investments to cover core costs are often
reported and/or projected by the global coordinators of
ADC/E/E programs as part of financial resource re-
quirements (FRRs). [64], (Measles Rubella Initiative:
Measles and Measles-Rubella SIA Forecast 2013–2018.
Unpublished).
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Additional file 1: contains three datasets: (1) cMYP data– the
country- reported data extracted from individual cMYPs and
adjusted for inflation. Used for the analysis of operational costs; (2) SIA
budget data– the country-reported data extracted from various sources
and adjusted for inflation. Used for the analysis of the cost components
that drive SIA costs; (3) Reference-style data—the demographic,
immunization system performance, or economic data (e.g. population,
vaccination coverage, per capita income, deflators) from third party
multilateral sources. Used to categorize country level data and/or create
population-weighted average benchmarks.
Additional file 2: contains additional summary results and data
used in analysis of SIA operation costs and SIA budget breakdowns.
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